

Independent Auditor's Review Report on Standalone unaudited financial results of GKB Ophthalmics Limited for the quarter ended June 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of GKB Ophthalmics Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of GKB Ophthalmics Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

NITIN
MANOHAR
JUMANI

Digitally signed by
NITIN MANOHAR
JUMANI
Date: 2025.08.14
15:02:50 +05'30'

Nitin Manohar Juman
Partner
Membership No.:111700
UDIN: 25111700BMKSJV7154

Place: Pune
Date: August 14, 2025



GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526
Tel No. (083) 6714444, E-mail: gkbophthalmics@gkb.net

Website: www.gkb.net

Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2025

(Rs. In Lakhs except earnings per share data)

	Particulars	Quarter Ended			Year Ended
		June 30, 2025 (Unaudited)	March 31, 2025 (Refer Note 3)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
	Income:				
1	Revenue from operations	877.49	842.63	861.90	3,274.94
2	Other income	7.01	1.10	8.93	197.22
3	Total income (1+2)	884.50	843.73	870.83	3,472.16
	Expenses:				
4	a) Cost of materials consumed	513.19	481.28	487.22	1,889.59
	b) Purchases of stock -in-trade	-	0.17	1.76	6.53
	c) Changes in inventories of finished goods and work-in-progress	(8.87)	21.76	(14.03)	(49.82)
	d) Employee benefits expense	283.71	272.72	266.59	1,088.35
	e) Finance costs	68.49	59.73	41.08	188.67
	f) Depreciation and amortisation expense	66.81	66.44	65.00	264.31
	g) Other expenses	173.68	185.43	162.94	688.16
	Total expenses	1,097.01	1,087.53	1,010.56	4,075.79
5	Profit / (Loss) before tax (3-4)	(212.51)	(243.80)	(139.73)	(603.63)
6	Tax expenses				
	a) Current Tax	*	*	*	*
	b) Deferred Tax	1.79	4.15	1.00	7.16
	Total Tax expense	1.79	4.15	1.00	7.16
7	Profit / (Loss) for the periods / year (5-6)	(214.30)	(247.95)	(140.73)	(610.79)
8	Other comprehensive income:				
	Items that will not be reclassified to profit or loss				
	Remeasurement of post-employment defined benefit plans - gain / (loss)	(6.88)	(15.94)	(3.86)	(27.52)
	Income tax effect on above item	1.79	4.15	1.00	7.16
	Other comprehensive income / (loss) for the periods / year	(5.09)	(11.79)	(2.86)	(20.36)
9	Total Comprehensive income / (loss) for the periods / year (7+8)	(219.39)	(259.74)	(143.59)	(631.15)
10	Paid-up equity share capital (face value of share - Rs. 10 each fully paid up)	504.06	504.06	504.06	504.06
11	Reserves excluding revaluation reserve				1,263.36
12	Earnings Per Share (face value of Rs. 10 each)				
	(a) Basic (in Rs.)	(4.25)	(4.92)	(2.80)	(12.12)
	(b) Diluted (in Rs.)	(4.25)	(4.92)	(2.80)	(12.12)
	* Not Annualised	*	*	*	

See accompanying notes

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

- 1 The above unaudited standalone financial results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 14, 2025 which has been subjected to limited review by the statutory auditors of the Company, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The company operates in one primary segment only, i.e. Ophthalmics Lenses and therefore IND AS 108 - Operating Segment is not applicable.
- 3 The figures for the quarter ended March 31, 2025 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures of nine months ended December 31, 2024 which were subject to limited review by the statutory auditors of the company.
- 4 The figures of the previous year / periods have been reclassified / regrouped wherever necessary to confirm to current period.

**For and on behalf of the Board of Directors
of GKB Ophthalmics Limited**

**KRISHNA
GOPAL GUPTA**

Digitally signed by
KRISHNA GOPAL GUPTA
Date: 2025.08.14
14:51:58 +05'30'

Place : Mapusa - Goa
Date : August 14, 2025

K. G. Gupta
Managing Director
DIN : 00051863

Independent Auditor's Review Report on consolidated unaudited financial results of GKB Ophthalmics Limited for the quarter ended June 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of GKB Ophthalmics Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of GKB Ophthalmics Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') and its share of the net loss after tax and total comprehensive loss of its associate for the quarter ended June 30, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	GSV Ophthalmics Private Limited	Subsidiary
2	GKB Ophthalmics Products [FZE]	Wholly owned subsidiary
	(including its following Subsidiaries and Associate) Lensco -The Lens Company (Subsidiary) Prescription Optical Products LLC (Subsidiary) Prime Ophthalmic Products (PTY) Ltd (Subsidiary) GKB Vision FZC (Associate) - 49% Holding	

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in

Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of one subsidiary included in the Statement, whose interim financial information reflects total revenues of Rs. Nil, total net profit after tax and total comprehensive income of Rs. 31.46 lakhs for the quarter ended June 30, 2025 as considered in the Statement. These interim financial information have been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditor.

7. The Statement includes the interim financial information of two step-down subsidiaries which has not been reviewed by their auditors, whose interim financial information reflects total revenue of Rs. 118.91 lakhs, total net loss and total comprehensive loss of Rs. 7.19 lakhs for the quarter ended June 30, 2025, respectively, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of Rs. 1.36 lakhs for the quarter ended June 30, 2025 as considered in the Statement, in respect of an associate, based on its interim financial information which has not been reviewed by its auditor. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these step-down subsidiaries and an associate is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

NITIN
MANOHAR
JUMANI
Digitally signed by
NITIN MANOHAR
JUMANI
Date: 2025.08.14
15:03:53 +05'30'

Nitin Manohar Juman
Partner
Membership No.: 111700
UDIN: 25111700BMKSJW3737

Place: Pune
Date: August 14, 2025



GKB Ophthalmics Limited

CIN : L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526

Tel No. (0832) 6714444

E-mail: gkbophthalmics@gkb.net

Website: www.gkb.net

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2025

(Rs. In Lakhs except earnings per share data)

	Particulars	Quarter Ended			Year Ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
	Income:				
1	Revenue from operations	3,230.51	3,102.29	2,601.76	10,898.76
2	Other income	20.94	33.62	28.13	133.10
3	Total Income (1+2)	3,251.45	3,135.91	2,629.89	11,031.86
	Expenses:				
a)	Cost of materials consumed	662.66	646.17	513.97	2,115.32
b)	Purchases of stock in trade	1,862.11	1,868.01	1,224.98	6,175.65
c)	Changes in inventories of finished goods, stock in trade and work-in progress	(335.35)	(263.11)	(12.40)	(946.37)
d)	Employee benefits expense	479.85	453.84	403.58	1,725.74
e)	Finance costs	76.63	63.04	55.34	237.08
f)	Depreciation and amortisation expense	79.91	79.92	75.56	308.70
g)	Other expenses	480.62	682.69	367.52	2,106.67
	Total expenses	3,306.43	3,530.56	2,628.55	11,722.79
5	Profit / (Loss) before share of profit / (loss) of an associate and tax (3-4)	(54.98)	(394.65)	1.34	(690.93)
6	Share in profit / (loss) of an associate	(1.36)	1.20	14.72	18.31
7	Profit/(loss) before tax (5+6)	(56.34)	(393.45)	16.06	(672.62)
8	Tax expenses				
a)	Current Tax	5.94	14.84	4.56	28.74
b)	Prior Period Tax	-	0.44	-	(0.60)
c)	Deferred Tax	1.79	4.15	1.00	7.16
	Total Tax Expense	7.73	19.43	5.56	35.30
9	Profit / (loss) for the periods / year (7-8)	(64.07)	(412.88)	10.50	(707.92)
10	Other comprehensive Income :-				
	Items that will not be reclassified to profit or loss				
	Remeasurement of post-employment defined benefit plans - gain / (loss)	(6.88)	(15.94)	(3.86)	(27.52)
	Income tax effect on above item	1.79	4.15	1.00	7.16
	Other comprehensive Income / (loss) for the periods / year	(5.09)	(11.79)	(2.86)	(20.36)
11	Total Comprehensive income / (loss) for the periods / year (9+10)	(69.16)	(424.67)	7.64	(728.28)
12	Profit /(Loss) for the periods / year attributable to				
	Equity holders of the parent	(101.82)	(354.59)	(25.37)	(704.48)
	Non-controlling interest	37.75	(58.29)	35.87	(3.44)
	Total	(64.07)	(412.88)	10.50	(707.92)
	Other comprehensive income / (loss) for the periods / year attributable to				
	Equity holders of the parent	(5.09)	(11.79)	(2.86)	(20.36)
	Non-controlling interest	-	-	-	-
	Total	(5.09)	(11.79)	(2.86)	(20.36)
	Total Comprehensive income / (loss) for the periods / year attributable to				
	Equity holders of the parent	(106.91)	(366.38)	(28.23)	(724.84)
	Non-controlling interest	37.75	(58.29)	35.87	(3.44)
	Total	(69.16)	(424.67)	7.64	(728.28)
13	Paid-up equity share capital (face value of share - Rs. 10 each)	504.06	504.06	504.06	504.06
14	Reserves excluding revaluation reserve				4,699.83
15	Earnings Per Share (face value of Rs. 10 each)				
	(a) Basic (in Rs.)	(2.02)	(7.03)	(0.50)	(13.98)
	(b) Diluted (in Rs.)	(2.02)	(7.03)	(0.50)	(13.98)
	* Not Annualised	*	*	*	*

See accompanying notes



GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

Notes:

- 1 The unaudited consolidated financial results include results of the following companies :

Name of the Company	Relationship
1. GKB Ophthalmics Limited	Holding Company
2. GSV Ophthalmics Private Limited	Subsidiary
3. GKB Ophthalmics Products [FZE]	Wholly Owned Subsidiary
(including its following Subsidiaries and Associate)	
a. Lensco - The lens company (Subsidiary)	
b. Prescription Optical Products LLC (Subsidiary)	
c. Prime Ophthalmic Products (PTY) Ltd (Subsidiary)	
d. GKB Vision FZC (Associate - 49% Holding)	

- 2 The above unaudited consolidated financial results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 14, 2025 which has been subjected to limited review by the statutory auditors of the Company, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The Group operates in one primary segment only, i.e. Ophthalmics Lenses and therefore IND AS 108 - Operating Segment is not applicable.
- 4 The figures for the quarter ended March 31, 2025 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures of nine months ended December 31, 2024 which were subject to limited review by the statutory auditors of the company.
- 5 The figures of the previous year / periods have been reclassified / regrouped wherever necessary to confirm to current period.

**For and on behalf of the Board of Directors
of GKB Ophthalmics Limited**

KRISHNA
GOPAL
GUPTA

Digitally signed by
KRISHNA GOPAL
GUPTA
Date: 2025.08.14
14:53:20 +05'30'

K. G. Gupta
Managing Director
DIN : 00051863

Place : Mapusa - Goa
Date : August 14, 2025